Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8735-8742

  Zhao, Rongbao ^a   Chattopadhyay, Shrikanta ^a   Hanscom, Marie ^a   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; METESIND GLUCURONATE; METHOTREXATE; PEMETREXED; PLEVITREXED; RALTITREXED; TRITIUM;

ARTICLE; CELL GROWTH; CELL LINE; CELL MEMBRANE TRANSPORT; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; PH; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; RECEPTORS, CELL SURFACE; THYMIDYLATE SYNTHASE; TIME FACTORS;

EID: 11144237445     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0932     Document Type: Article

References (48)

1. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003;66:403-56.
2. Zhao R, Goldman JD. Resistance to antifolates. Oncogene 2003;22:7431-57.
3. Sierra EE, Goldman ID. Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochem Pharmacol 1998;55:1505-12.
4. Sierra EE, Brigle KE, Spinella MJ, Goldman ID. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells: further evidence for a third route mediated at low pH. Biochem Pharmacol 1997;53:223-31.
5. Vincent ML, Russell RM, Sasak V. Folic acid uptake characteristics of a human colon carcinoma cell line, Caco-2. A newly-described cellular model for small intestinal epithelium. Hum Nutr Clin Nutr 1985;39:355-60.
6. Henderson GB, Strauss BP. Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells. Cancer Res 1990;50:1709-14.
7. Kuhnel JM, Chiao JH, Sirotnak FM. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells. J Cell Physiol 2000;184:364-72.
8. Horne DW, Reed KA. Transport of methotrexate into PC-3 human prostate cancer cells. Arch Biochem Biophys 2001;394:39-44.
9. Chancy CD, Kekuda R, Huang W, et al. Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J Biol Chem 2000;275:20676-84.
10. Assaraf YG, Babani S, Goldman ID. Increased activity of a novel low pH folate transporter associated with lipoplilic antifolate resistance in Chinese hamster ovary cells. J Biol Chem 1998;273:8106-11.
11. Chiao JH, Roy K, Tolner B, Yang CH, Sirotnak FM. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem 1997;272:11165-70.
12. Kumar CK, Nguyen TT, Gonzales FB, Said HM. Comparison of intestinal folate carrier clone expressed in IEC-6 cells and in Xenopus oocytes. Am J Physiol 1998;274:C289-94.
13. Said HM, Chatterjee N, Haq RU, et al. Adaptive regulation of intestinal folate uptake: effect of dietary folate deficiency. Am J Physiol Cell Physiol 2000;279:C1889-95.
14. Said HM, Smith R, Redha R. Studies on the intestinal surface acid microclimate: developmental aspects. Pediatr Res 1987;22:497-9.
15. rd ed. New York: Raven Press; 1994. p. 1979-95.
16. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984;2:343-66.
17. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82.
18. 31P magnetic resonance spectroscopy. Biochem Pharmacol 1999;57:309-12.
19. Zhao R, Gao F, Hanscom M, Goldman ID. A prominent low-pH methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004;10:718-27.
20. Wang Y, Zhao R, Goldman ID. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res 2004;10:6256-64.
21. Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res 2004;64:3313-9.
22. Fry DW, Yalowich JC, Goldman ID. Rapid formation of polygamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem 1982;257:1890-6.
23. Wang Y, Zhao R, Chattopadhyay S, Goldman ID. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res 2002;62:6434-7.
24. Wang Y, Zhao R, Chattopadhyay S, Goldman ID. Correction Cancer Res 2003;63:7004.
25. Stanford WL, Cohn JB, Cordes SP. Gene-trap mutagenesis: past, present and beyond. Nat Rev Genet 2001;2:756-68.
26. Vallis KA, Chen Z, Stanford WL, et al. Identification of radiation-responsive genes in vitro using a gene trap strategy predicts for modulation of expression by radiation in vivo. Radiat Res 2002;157:8-18.
27. Baghdoyan S, Dubreuil P, Eberle F, Gomez S. Capture of cytokine-responsive genes (NACA and RBM3) using a gene trap approach. Blood 2000;95:3750-7.
28. Friedrich G, Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev 1991;5:1513-23.
29. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (Bethesda) 1990;82:1107-12.
30. Sharif KA, Goldman ID. Rapid determination of membrane transport parameters in adherent cells. BioTechniques 2000;28:926-8, 930, 932.
31. Bowen D, Diasio RB, Goldman ID. Distinguishing between membrane transport and intracellular metabolism of fluorodeoxyuridine in Ehrlich ascites tumor cells by application of kinetic and high performance liquid chromatographic techniques. J Biol Chem 1979;254:5333-9.
32. Lowe AG, Walmsley AR. The kinetics of glucose transport in human red blood cells. Biochim Biophys Acta 1986;857:146-54.
33. Goldman ID. A model system for the study of heteroexchange diffusion: methotrexate-folate interactions in L1210 leukemia and Ehrlich ascites tumor cells. Biochim Biophys Acta 1971;233:624-34.
34. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
35. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
36. Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H. Review of a promising new agent - pemetrexed disodium. Cancer 2003;97:2056-63.
37. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65.
38. Tse A, Moran RG. Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites. J Biol Chem 1998;273:25944-52.
39. Jansen G, Barr H, Kathmann I, et al. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761-9.
40. Stark M, Rothem L, Jansen G, et al. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol Pharmacol 2003;64:220-7.
41. Assaraf YG, Goldman ID. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 1997;272:17460-6.
42. Seither RL, Trent DF, Mikullecky DC, Rape TJ, Goldman ID. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. J Biol Chem 1989;264:17016-23.
43. Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-95.
44. Andreassi JL, Moran RG. Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 2002;41:226-35.
45. Habeck LL, Mendelsohn LG, Shih C, et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995;48:326-33.
46. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579-86.
47. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23.
48. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6,N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4.